Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

Inclusion Criteria: Part 1 and 2 (Healthy Volunteers)

• Male between ages 18-50 years

• Willing and able to provide informed consent

Willing to follow protocol-specified contraception requirement

Inclusion Criteria: Part 3 (CHB Subjects)

• Male or female subjects between the ages of 18-60 years

• Willing to provide informed consent

• Chronic HBV infection for at least 6 months

• Willing to follow protocol-specified contraception requirement

Exclusion Criteria: Part 1 and 2 (Healthy Volunteers)

Key Exclusion Criteria:

• Clinically significant lab abnormalities

• A history of clinically significant gastrointestinal, hematologic, renal, hepatic,bronchopulmonary, neurological, psychiatric, cardiovascular, autoimmune or otherimmune-mediated disease.

• HIV or Hep C positive

• Known chronic or severe infection or recent significant exposure to infections suchas tuberculosis or endemic mycosis, untreated latent infections like tuberculosis,or a positive or indeterminate QuantiFERON test.

Exclusion Criteria: Part 3 (CHB Subjects)

• Have extensive fibrosis or cirrhosis of the liver

• Have or had liver cancer (hepatocellular carcinoma)

• Have a history or current autoimmune disease or has been on immunosuppressivemedications within 6 months of the start of the study

• Females who breastfeeding, pregnant or who wish to become pregnant during the study

• Known chronic or severe infection or recent significant exposure to infections suchas tuberculosis or endemic mycosis, untreated latent infections like tuberculosis,or a positive or indeterminate QuantiFERON test.